Global Heart Failure POC and LOC Devices Market - 2025 -2033
Heart Failure POC and LOC Devices Market Size
Heart Failure POC and LOC Devices Market Size reached US$ 127.79 Million in 2024 from US$ 112.17 Million in 2023 and is expected to reach US$ 451.93 Million by 2033, growing at a CAGR of 15.2% during the forecast period 2025-2033.
Heart Failure POC and LOC Devices Market Overview
The heart failure Point-of-Care (POC) and Lab-on-Chip (LOC) devices market is on a rapid expansion path. Its growth is underpinned by strong epidemiological trends, breakthrough microfluidic and biosensor technologies, and a fundamental shift toward decentralized, value-based healthcare.
While challenges persist, particularly around reimbursement and multi-analyte validation, the momentum toward personalized, real-time heart failure diagnostics remains powerful, heralding a new era of improved patient outcomes, reduced healthcare costs, and more proactive disease management. This growth reflects expanding demand for rapid, near-patient diagnostic and monitoring solutions that enable early intervention, reduce hospital readmissions, and facilitate personalized therapy adjustments for heart failure patients.
Heart Failure POC and LOC Devices Market Dynamics
Drivers:
Rising technological advancements are significantly driving the heart failure POC and LOC devices market growth
Advances in microfluidics and nanotechnology have enabled the development of highly compact LOC devices that can perform complex biomarker analyses (e.g., BNP, NT-proBNP, ST2) using just a tiny blood sample. This makes testing faster and less invasive, ideal for home or outpatient use. Modern LOC platforms can now detect multiple heart failure-related biomarkers simultaneously, improving diagnostic precision and risk stratification.
For instance, in April 2024, Roche Diagnostics India introduced its point-of-care NT-proBNP test, targeting diabetes patients at risk of cardiovascular diseases like heart failure (HF). This advanced test, available exclusively system, aims to streamline patient care by offering quicker and more accurate diagnosis and management of HF in type 2 diabetes (T2D) patients.
Technological progress in Bluetooth, Wi-Fi, and cloud computing facilitates real-time data transmission from POC devices to healthcare providers. AI algorithms analyze longitudinal biomarker data to predict decompensation episodes earlier, supporting remote patient management. Modern LOC platforms can now detect multiple heart failure-related biomarkers simultaneously, improving diagnostic precision and risk stratification. For example, devices measuring NT-proBNP alongside inflammatory markers provide clinicians with a more comprehensive clinical picture.
The rising prevalence of heart failure is also driving the heart failure POC and LOC devices market growth
According to the Heart Failure Society of America, approximately 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.7 million in 2030, 10.3 million in 2040, and 11.4 million by 2050. As heart failure affects more people worldwide, driven by aging populations, rising rates of diabetes and hypertension, and improved survival after acute cardiac events, the demand for rapid, near-patient diagnostics has surged.
In many busy hospitals, acute dyspnea presentations have risen in parallel with heart failure prevalence. To quickly distinguish heart failure from other causes (like pneumonia or COPD exacerbations), emergency physicians now routinely use handheld BNP/NT-proBNP POC tests.
As more patients develop chronic heart failure, outpatient clinics and home-care programs have expanded their use of LOC devices for weekly or biweekly biomarker checks. In a pilot project in Germany, a cardiology practice equipped 150 stable heart failure patients with a home-use NT-proBNP LOC kit linked to a smartphone app. Over six months, those whose rising NT-proBNP levels triggered early nurse follow-up saw a 30 percent reduction in 90-day readmission rates compared to matched controls. This kind of data?driven intervention boosts the market growth.
Restraints:
Data security and interoperability concerns are hampering the growth of the heart failure POC and LOC devices market
Many POC/LOC systems transmit sensitive biomarker data (e.g., NT-proBNP levels) over Wi-Fi or cellular networks to cloud servers. Hospitals and home-care programs worry about HIPAA (U.S.) or GDPR (EU) violations if data isn’t fully encrypted end-to-end.
For instance, according to the HIPAA Journal, in 2024, the protected health information of 276,775,457 individuals was exposed or stolen. On average, that is 758,288 records per day. In March 2025, 1,754,097 individuals had their protected health information exposed, stolen, or impermissibly disclosed in a healthcare data breach.
Many LOC platforms rely on proprietary apps or dashboards, which don’t speak HL7/FHIR standards that hospital EHRs use. As a result, cardiology practices must maintain separate portals for POC results, fragmenting clinician workflows. Wearable sensors that complement POC/LOC devices, tracking heart rate variability or thoracic impedance, also transmit data continuously. If attackers breach these endpoints, they might gain persistent access to patient networks or launch ransomware attacks on hospital systems.
Opportunities:
Integration of AI and predictive analytics in POC devices creates a market opportunity for the heart failure POC and LOC devices market
The integration of AI and predictive analytics in heart failure POC and LOC devices is creating significant market opportunities by enabling earlier, more accurate detection and personalized management of heart failure, which leads to better patient outcomes and reduced healthcare costs. AI algorithms analyze large datasets from POC devices, including biomarkers, patient history, and vital signs, to predict heart failure exacerbations before symptoms worsen. This allows timely interventions and reduces hospital admissions.
Biofourmis, a digital health company, uses AI-powered wearable sensors combined with LOC biomarker tests to predict heart failure readmissions up to 6 days in advance, reducing readmission rates by 50% in pilot studies. AI and predictive analytics transform heart failure POC and LOC devices from simple diagnostic tools into proactive, personalized management systems. This creates strong market demand by improving patient outcomes, reducing costs, and offering healthcare providers powerful decision-support tools, making AI integration a key opportunity for market growth.
Heart Failure POC and LOC Devices Market Segment Analysis
The global heart failure POC and LOC devices market is segmented based on test type, technology, product type, end-user, and region.
Proteomic testing from the test type segment is expected to hold 45.39% of the market share in 2024 in the heart failure POC and LOC devices market
Two types of biomarkers can be used: heart-specific markers and markers that monitor the cardiovascular and pulmonary systems. Some common peptides assessed to monitor cardiovascular events include N-terminal pro-B-type natriuretic peptide (NTproBNP), troponin, and B-type natriuretic peptide (BNP). Troponin T (TnT) and Troponin I (TnI) are the most specific protein biomarkers linked to myocardial infarction. As a result, most companies have targeted this biomarker as a key revenue-generating segment. The estimated share of proteomic testing is influenced by the presence of many commercial POC devices based on protein marker testing.
BNP and NT-proBNP have decades of large?scale clinical studies proving their sensitivity and specificity for diagnosing, risk-stratifying, and monitoring HF. Major guidelines (ACC/AHA, ESC) recommend using these markers for acute dyspnea triage and chronic HF management. Payers and hospitals are therefore comfortable reimbursing and implementing proteomic assays in decentralized settings.
Antibody?based immunoassays for BNP or troponin can be miniaturized onto lateral-flow cartridges or microfluidic chips with well-established capture/detection chemistries. This has led to a proliferation of FDA-cleared/CE-marked products such as Abbott i-STAT BNP, a handheld analyzer that delivers BNP results from a 20 µL finger-stick in ~10 minutes, now standard in many U.S. EDs for rapid dyspnea evaluation, and Roche cobas h 232 NT-proBNP, a compact POC reader used in ambulances and clinics, offering NT-proBNP quantitation in ~12 minutes with a single-use cartridge.
Because BNP/NT-proBNP levels rise before overt symptoms, POC/LOC proteomic tests allow early decompensation detection (often 2–3 days in advance). As proteomic biomarkers are so tightly linked to both acute triage decisions and longitudinal therapy adjustments, and because POC/LOC platforms have proved reliable for these assays, proteomic testing continues to capture the largest share of the heart failure POC/LOC devices market.
Heart Failure POC and LOC Devices Market Geographical Analysis
North America is expected to dominate the global heart failure POC and LOC devices market with a 41.94% share in 2024
Many leading LOC and POC market players, such as Abbott, Thermo Fisher, and Quidel, have U.S. or Canadian headquarters. Their proximity to NIH and NIH-funded clinical trials accelerates validation studies. North American firms frequently leverage the FDA’s Breakthrough Devices program to fast-track multiplex LOC chips. Once cleared, obtaining a CLIA waiver for true point-of-care use (even in small clinics or home settings) is relatively straightforward, driving broader deployment.
Heart Failure Society of America, approximately 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.7 million in 2030, 10.3 million in 2040, and 11.4 million by 2050. Approximately one-third of the adult population in the United States (US) is at risk for HF (Stage A), and 24-34% of the US population has pre-HF (Stage B). The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime. To manage this burden, North American providers have pioneered home-care models: visiting nurses use handheld POC readers (e.g., Roche’s cobas h 232) on weekly patient visits, feeding data into cloud-based dashboards for cardiologist review.
Asia-Pacific is growing at the fastest pace in the heart failure POC and LOC devices market, holding 20.14% of the market share
Rapid urbanization, changing lifestyles, and aging populations have led to an increase in cardiovascular diseases, including heart failure, in countries like China, India, and Japan. This fuels demand for efficient, accessible diagnostic tools like POC and LOC devices. Many APAC countries are investing heavily in healthcare modernization, including establishing advanced diagnostic facilities and promoting remote healthcare solutions, which boost the adoption of portable and easy-to-use POC devices.
Governments are launching programs to improve early diagnosis and management of chronic diseases. For instance, China’s “Healthy China 2030” plan emphasizes improving cardiovascular health, supporting the market. Due to large rural populations and limited access to hospitals, POC and LOC devices integrated with telehealth are gaining traction for remote patient management.
Heart Failure POC and LOC Devices Market Top Companies
Top companies in the heart failure POC and LOC devices market include Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthineers, QuidelOrtho Corporation, Jant Pharmacal Corporation, Trinity Biotech, bioM?rieux, and Beckman Coulter, Inc., among others.
The global heart failure POC and LOC devices market report delivers a detailed analysis with 64 key tables, more than 63 visually impactful figures, and 165 pages of expert insights, providing a complete view of the market landscape.
Heart Failure POC and LOC Devices Market Size reached US$ 127.79 Million in 2024 from US$ 112.17 Million in 2023 and is expected to reach US$ 451.93 Million by 2033, growing at a CAGR of 15.2% during the forecast period 2025-2033.
Heart Failure POC and LOC Devices Market Overview
The heart failure Point-of-Care (POC) and Lab-on-Chip (LOC) devices market is on a rapid expansion path. Its growth is underpinned by strong epidemiological trends, breakthrough microfluidic and biosensor technologies, and a fundamental shift toward decentralized, value-based healthcare.
While challenges persist, particularly around reimbursement and multi-analyte validation, the momentum toward personalized, real-time heart failure diagnostics remains powerful, heralding a new era of improved patient outcomes, reduced healthcare costs, and more proactive disease management. This growth reflects expanding demand for rapid, near-patient diagnostic and monitoring solutions that enable early intervention, reduce hospital readmissions, and facilitate personalized therapy adjustments for heart failure patients.
Heart Failure POC and LOC Devices Market Dynamics
Drivers:
Rising technological advancements are significantly driving the heart failure POC and LOC devices market growth
Advances in microfluidics and nanotechnology have enabled the development of highly compact LOC devices that can perform complex biomarker analyses (e.g., BNP, NT-proBNP, ST2) using just a tiny blood sample. This makes testing faster and less invasive, ideal for home or outpatient use. Modern LOC platforms can now detect multiple heart failure-related biomarkers simultaneously, improving diagnostic precision and risk stratification.
For instance, in April 2024, Roche Diagnostics India introduced its point-of-care NT-proBNP test, targeting diabetes patients at risk of cardiovascular diseases like heart failure (HF). This advanced test, available exclusively system, aims to streamline patient care by offering quicker and more accurate diagnosis and management of HF in type 2 diabetes (T2D) patients.
Technological progress in Bluetooth, Wi-Fi, and cloud computing facilitates real-time data transmission from POC devices to healthcare providers. AI algorithms analyze longitudinal biomarker data to predict decompensation episodes earlier, supporting remote patient management. Modern LOC platforms can now detect multiple heart failure-related biomarkers simultaneously, improving diagnostic precision and risk stratification. For example, devices measuring NT-proBNP alongside inflammatory markers provide clinicians with a more comprehensive clinical picture.
The rising prevalence of heart failure is also driving the heart failure POC and LOC devices market growth
According to the Heart Failure Society of America, approximately 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.7 million in 2030, 10.3 million in 2040, and 11.4 million by 2050. As heart failure affects more people worldwide, driven by aging populations, rising rates of diabetes and hypertension, and improved survival after acute cardiac events, the demand for rapid, near-patient diagnostics has surged.
In many busy hospitals, acute dyspnea presentations have risen in parallel with heart failure prevalence. To quickly distinguish heart failure from other causes (like pneumonia or COPD exacerbations), emergency physicians now routinely use handheld BNP/NT-proBNP POC tests.
As more patients develop chronic heart failure, outpatient clinics and home-care programs have expanded their use of LOC devices for weekly or biweekly biomarker checks. In a pilot project in Germany, a cardiology practice equipped 150 stable heart failure patients with a home-use NT-proBNP LOC kit linked to a smartphone app. Over six months, those whose rising NT-proBNP levels triggered early nurse follow-up saw a 30 percent reduction in 90-day readmission rates compared to matched controls. This kind of data?driven intervention boosts the market growth.
Restraints:
Data security and interoperability concerns are hampering the growth of the heart failure POC and LOC devices market
Many POC/LOC systems transmit sensitive biomarker data (e.g., NT-proBNP levels) over Wi-Fi or cellular networks to cloud servers. Hospitals and home-care programs worry about HIPAA (U.S.) or GDPR (EU) violations if data isn’t fully encrypted end-to-end.
For instance, according to the HIPAA Journal, in 2024, the protected health information of 276,775,457 individuals was exposed or stolen. On average, that is 758,288 records per day. In March 2025, 1,754,097 individuals had their protected health information exposed, stolen, or impermissibly disclosed in a healthcare data breach.
Many LOC platforms rely on proprietary apps or dashboards, which don’t speak HL7/FHIR standards that hospital EHRs use. As a result, cardiology practices must maintain separate portals for POC results, fragmenting clinician workflows. Wearable sensors that complement POC/LOC devices, tracking heart rate variability or thoracic impedance, also transmit data continuously. If attackers breach these endpoints, they might gain persistent access to patient networks or launch ransomware attacks on hospital systems.
Opportunities:
Integration of AI and predictive analytics in POC devices creates a market opportunity for the heart failure POC and LOC devices market
The integration of AI and predictive analytics in heart failure POC and LOC devices is creating significant market opportunities by enabling earlier, more accurate detection and personalized management of heart failure, which leads to better patient outcomes and reduced healthcare costs. AI algorithms analyze large datasets from POC devices, including biomarkers, patient history, and vital signs, to predict heart failure exacerbations before symptoms worsen. This allows timely interventions and reduces hospital admissions.
Biofourmis, a digital health company, uses AI-powered wearable sensors combined with LOC biomarker tests to predict heart failure readmissions up to 6 days in advance, reducing readmission rates by 50% in pilot studies. AI and predictive analytics transform heart failure POC and LOC devices from simple diagnostic tools into proactive, personalized management systems. This creates strong market demand by improving patient outcomes, reducing costs, and offering healthcare providers powerful decision-support tools, making AI integration a key opportunity for market growth.
Heart Failure POC and LOC Devices Market Segment Analysis
The global heart failure POC and LOC devices market is segmented based on test type, technology, product type, end-user, and region.
Proteomic testing from the test type segment is expected to hold 45.39% of the market share in 2024 in the heart failure POC and LOC devices market
Two types of biomarkers can be used: heart-specific markers and markers that monitor the cardiovascular and pulmonary systems. Some common peptides assessed to monitor cardiovascular events include N-terminal pro-B-type natriuretic peptide (NTproBNP), troponin, and B-type natriuretic peptide (BNP). Troponin T (TnT) and Troponin I (TnI) are the most specific protein biomarkers linked to myocardial infarction. As a result, most companies have targeted this biomarker as a key revenue-generating segment. The estimated share of proteomic testing is influenced by the presence of many commercial POC devices based on protein marker testing.
BNP and NT-proBNP have decades of large?scale clinical studies proving their sensitivity and specificity for diagnosing, risk-stratifying, and monitoring HF. Major guidelines (ACC/AHA, ESC) recommend using these markers for acute dyspnea triage and chronic HF management. Payers and hospitals are therefore comfortable reimbursing and implementing proteomic assays in decentralized settings.
Antibody?based immunoassays for BNP or troponin can be miniaturized onto lateral-flow cartridges or microfluidic chips with well-established capture/detection chemistries. This has led to a proliferation of FDA-cleared/CE-marked products such as Abbott i-STAT BNP, a handheld analyzer that delivers BNP results from a 20 µL finger-stick in ~10 minutes, now standard in many U.S. EDs for rapid dyspnea evaluation, and Roche cobas h 232 NT-proBNP, a compact POC reader used in ambulances and clinics, offering NT-proBNP quantitation in ~12 minutes with a single-use cartridge.
Because BNP/NT-proBNP levels rise before overt symptoms, POC/LOC proteomic tests allow early decompensation detection (often 2–3 days in advance). As proteomic biomarkers are so tightly linked to both acute triage decisions and longitudinal therapy adjustments, and because POC/LOC platforms have proved reliable for these assays, proteomic testing continues to capture the largest share of the heart failure POC/LOC devices market.
Heart Failure POC and LOC Devices Market Geographical Analysis
North America is expected to dominate the global heart failure POC and LOC devices market with a 41.94% share in 2024
Many leading LOC and POC market players, such as Abbott, Thermo Fisher, and Quidel, have U.S. or Canadian headquarters. Their proximity to NIH and NIH-funded clinical trials accelerates validation studies. North American firms frequently leverage the FDA’s Breakthrough Devices program to fast-track multiplex LOC chips. Once cleared, obtaining a CLIA waiver for true point-of-care use (even in small clinics or home settings) is relatively straightforward, driving broader deployment.
Heart Failure Society of America, approximately 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.7 million in 2030, 10.3 million in 2040, and 11.4 million by 2050. Approximately one-third of the adult population in the United States (US) is at risk for HF (Stage A), and 24-34% of the US population has pre-HF (Stage B). The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime. To manage this burden, North American providers have pioneered home-care models: visiting nurses use handheld POC readers (e.g., Roche’s cobas h 232) on weekly patient visits, feeding data into cloud-based dashboards for cardiologist review.
Asia-Pacific is growing at the fastest pace in the heart failure POC and LOC devices market, holding 20.14% of the market share
Rapid urbanization, changing lifestyles, and aging populations have led to an increase in cardiovascular diseases, including heart failure, in countries like China, India, and Japan. This fuels demand for efficient, accessible diagnostic tools like POC and LOC devices. Many APAC countries are investing heavily in healthcare modernization, including establishing advanced diagnostic facilities and promoting remote healthcare solutions, which boost the adoption of portable and easy-to-use POC devices.
Governments are launching programs to improve early diagnosis and management of chronic diseases. For instance, China’s “Healthy China 2030” plan emphasizes improving cardiovascular health, supporting the market. Due to large rural populations and limited access to hospitals, POC and LOC devices integrated with telehealth are gaining traction for remote patient management.
Heart Failure POC and LOC Devices Market Top Companies
Top companies in the heart failure POC and LOC devices market include Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthineers, QuidelOrtho Corporation, Jant Pharmacal Corporation, Trinity Biotech, bioM?rieux, and Beckman Coulter, Inc., among others.
The global heart failure POC and LOC devices market report delivers a detailed analysis with 64 key tables, more than 63 visually impactful figures, and 165 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Test Type
3.3. Snippet by Technology
3.4. Snippet by Product Type
3.5. Snippet by End-User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Technological Advancements
4.1.1.2. Rising Prevalence of Heart Failure
4.1.2. Restraints
4.1.2.1. High Cost of Advanced Devices and Limited Reimbursement
4.1.2.2. Data Security and Interoperability Concerns
4.1.3. Opportunity
4.1.3.1. Integration of AI and Predictive Analytics in POC Devices
4.1.3.2. Miniaturization and Battery-Free Operation
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. Unmet Needs and Gaps
5.9. Recommended Strategies for Market Entry and Expansion
5.10. Pricing Analysis and Price Dynamics
6. HEART FAILURE POC AND LOC DEVICES MARKET, BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Proteomic Testing*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Metabolomic Testing
6.4. Genomic Testing
7. HEART FAILURE POC AND LOC DEVICES MARKET, BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Microfluidics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Array-Based Systems
7.4. Others
8. HEART FAILURE POC AND LOC DEVICES MARKET, BY PRODUCT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. Wearable Devices*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Implantable Devices
8.4. Handheld Devices
9. HEART FAILURE POC AND LOC DEVICES MARKET, BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Homecare Settings
9.5. Assisted Living Healthcare Facilities
9.6. Laboratories
9.7. Others
10. HEART FAILURE POC AND LOC DEVICES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. China
10.4.7.2. India
10.4.7.3. Japan
10.4.7.4. South Korea
10.4.7.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. Brazil
10.5.7.2. Argentina
10.5.7.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
12.1. Market Share Analysis and Positioning Matrix
12.2. Strategic Partnerships, Mergers & Acquisitions
12.3. Key Developments in Product Portfolios and Innovations
12.4. Company Benchmarking
13. COMPANY PROFILES
13.1. Abbott*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.4.4. SWOT Analysis
13.2. F. Hoffmann-La Roche Ltd
13.3. Siemens Healthineers
13.4. QuidelOrtho Corporation
13.5. Jant Pharmacal Corporation
13.6. Trinity Biotech
13.7. bioM?rieux
13.8. Beckman Coulter, Inc. ( LIST NOT EXHAUSTIVE )
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Test Type
3.3. Snippet by Technology
3.4. Snippet by Product Type
3.5. Snippet by End-User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Technological Advancements
4.1.1.2. Rising Prevalence of Heart Failure
4.1.2. Restraints
4.1.2.1. High Cost of Advanced Devices and Limited Reimbursement
4.1.2.2. Data Security and Interoperability Concerns
4.1.3. Opportunity
4.1.3.1. Integration of AI and Predictive Analytics in POC Devices
4.1.3.2. Miniaturization and Battery-Free Operation
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. Unmet Needs and Gaps
5.9. Recommended Strategies for Market Entry and Expansion
5.10. Pricing Analysis and Price Dynamics
6. HEART FAILURE POC AND LOC DEVICES MARKET, BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Proteomic Testing*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Metabolomic Testing
6.4. Genomic Testing
7. HEART FAILURE POC AND LOC DEVICES MARKET, BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Microfluidics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Array-Based Systems
7.4. Others
8. HEART FAILURE POC AND LOC DEVICES MARKET, BY PRODUCT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. Wearable Devices*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Implantable Devices
8.4. Handheld Devices
9. HEART FAILURE POC AND LOC DEVICES MARKET, BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Homecare Settings
9.5. Assisted Living Healthcare Facilities
9.6. Laboratories
9.7. Others
10. HEART FAILURE POC AND LOC DEVICES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. China
10.4.7.2. India
10.4.7.3. Japan
10.4.7.4. South Korea
10.4.7.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. Brazil
10.5.7.2. Argentina
10.5.7.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
12.1. Market Share Analysis and Positioning Matrix
12.2. Strategic Partnerships, Mergers & Acquisitions
12.3. Key Developments in Product Portfolios and Innovations
12.4. Company Benchmarking
13. COMPANY PROFILES
13.1. Abbott*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.4.4. SWOT Analysis
13.2. F. Hoffmann-La Roche Ltd
13.3. Siemens Healthineers
13.4. QuidelOrtho Corporation
13.5. Jant Pharmacal Corporation
13.6. Trinity Biotech
13.7. bioM?rieux
13.8. Beckman Coulter, Inc. ( LIST NOT EXHAUSTIVE )
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
LIST OF TABLES
Table 1 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Heart Failure POC and LOC Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 8 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 10 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 11 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 12 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 13 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 14 Global Heart Failure POC and LOC Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 15 Global Heart Failure POC and LOC Devices Market Value, By Region, 2022-2033 (US$ Million)
Table 16 North America Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 17 North America Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 18 North America Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 19 North America Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 20 North America Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 22 Europe Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 23 Europe Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 24 Europe Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 25 Europe Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 26 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 27 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 28 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 29 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 30 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 31 South America Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 32 South America Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 33 South America Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 34 South America Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 35 South America Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 36 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 37 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 38 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 39 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 40 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 41 Abbott: Overview
Table 42 Abbott: Product Portfolio
Table 43 Abbott: Key Developments
Table 44 F. Hoffmann-La Roche Ltd: Overview
Table 45 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 46 F. Hoffmann-La Roche Ltd: Key Developments
Table 47 Siemens Healthineers: Overview
Table 48 Siemens Healthineers: Product Portfolio
Table 49 Siemens Healthineers: Key Developments
Table 50 QuidelOrtho Corporation: Overview
Table 51 QuidelOrtho Corporation: Product Portfolio
Table 52 QuidelOrtho Corporation: Key Developments
Table 53 Jant Pharmacal Corporation: Overview
Table 54 Jant Pharmacal Corporation: Product Portfolio
Table 55 Jant Pharmacal Corporation: Key Developments
Table 56 Trinity Biotech: Overview
Table 57 Trinity Biotech: Product Portfolio
Table 58 Trinity Biotech: Key Developments
Table 59 bioM?rieux: Overview
Table 60 bioM?rieux: Product Portfolio
Table 61 bioM?rieux: Key Developments
Table 62 Beckman Coulter, Inc.: Overview
Table 63 Beckman Coulter, Inc.: Product Portfolio
Table 64 Beckman Coulter, Inc.: Key Developments
Table 1 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Heart Failure POC and LOC Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 8 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 10 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 11 Global Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 12 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 13 Global Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 14 Global Heart Failure POC and LOC Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 15 Global Heart Failure POC and LOC Devices Market Value, By Region, 2022-2033 (US$ Million)
Table 16 North America Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 17 North America Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 18 North America Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 19 North America Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 20 North America Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 22 Europe Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 23 Europe Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 24 Europe Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 25 Europe Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 26 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 27 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 28 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 29 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 30 Asia-Pacific Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 31 South America Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 32 South America Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 33 South America Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 34 South America Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 35 South America Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 36 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Test Type, 2022-2033 (US$ Million)
Table 37 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Technology, 2022-2033 (US$ Million)
Table 38 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Product Type, 2022-2033 (US$ Million)
Table 39 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By End-User, 2022-2033 (US$ Million)
Table 40 Middle East and Africa Heart Failure POC and LOC Devices Market Value, By Country, 2022-2033 (US$ Million)
Table 41 Abbott: Overview
Table 42 Abbott: Product Portfolio
Table 43 Abbott: Key Developments
Table 44 F. Hoffmann-La Roche Ltd: Overview
Table 45 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 46 F. Hoffmann-La Roche Ltd: Key Developments
Table 47 Siemens Healthineers: Overview
Table 48 Siemens Healthineers: Product Portfolio
Table 49 Siemens Healthineers: Key Developments
Table 50 QuidelOrtho Corporation: Overview
Table 51 QuidelOrtho Corporation: Product Portfolio
Table 52 QuidelOrtho Corporation: Key Developments
Table 53 Jant Pharmacal Corporation: Overview
Table 54 Jant Pharmacal Corporation: Product Portfolio
Table 55 Jant Pharmacal Corporation: Key Developments
Table 56 Trinity Biotech: Overview
Table 57 Trinity Biotech: Product Portfolio
Table 58 Trinity Biotech: Key Developments
Table 59 bioM?rieux: Overview
Table 60 bioM?rieux: Product Portfolio
Table 61 bioM?rieux: Key Developments
Table 62 Beckman Coulter, Inc.: Overview
Table 63 Beckman Coulter, Inc.: Product Portfolio
Table 64 Beckman Coulter, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 2 Global Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 3 Global Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 5 Global Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Heart Failure POC and LOC Devices Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 8 Proteomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 9 Metabolomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 10 Genomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 11 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 12 Microfluidics Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 13 Array-Based Systems Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 14 Others Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 15 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 16 Wearable Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 17 Implantable Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 18 Handheld Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 19 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 20 Hospitals End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 21 Specialty Clinics End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 22 Homecare Settings End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 23 Assisted Living Healthcare Facilities End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 24 Laboratories End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 25 Others End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 26 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 28 North America Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 29 North America Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 30 North America Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 31 North America Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 33 Europe Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 34 Europe Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 35 Europe Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 36 Europe Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 37 Europe Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Europe Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 39 Asia-Pacific Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 40 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 41 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 42 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 46 South America Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 47 South America Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 48 South America Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 49 South America Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 52 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 54 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott: Financials
Figure 57 F. Hoffmann-La Roche Ltd: Financials
Figure 58 Siemens Healthineers: Financials
Figure 59 QuidelOrtho Corporation: Financials
Figure 60 Jant Pharmacal Corporation: Financials
Figure 61 Trinity Biotech: Financials
Figure 62 bioM?rieux: Financials
Figure 63 Beckman Coulter, Inc.: Financials
Figure 1 Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 2 Global Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 3 Global Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 5 Global Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Heart Failure POC and LOC Devices Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 8 Proteomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 9 Metabolomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 10 Genomic Testing Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 11 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 12 Microfluidics Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 13 Array-Based Systems Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 14 Others Technology in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 15 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 16 Wearable Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 17 Implantable Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 18 Handheld Devices Product Type in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 19 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 20 Hospitals End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 21 Specialty Clinics End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 22 Homecare Settings End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 23 Assisted Living Healthcare Facilities End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 24 Laboratories End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 25 Others End-User in Global Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 26 Global Heart Failure POC and LOC Devices Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 28 North America Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 29 North America Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 30 North America Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 31 North America Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 33 Europe Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 34 Europe Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 35 Europe Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 36 Europe Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 37 Europe Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Europe Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 39 Asia-Pacific Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 40 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 41 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 42 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Asia-Pacific Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 46 South America Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 47 South America Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 48 South America Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 49 South America Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Heart Failure POC and LOC Devices Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Heart Failure POC and LOC Devices Market Value, 2022-2033 (US$ Million)
Figure 52 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Test Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Technology, 2024 & 2033 (%)
Figure 54 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Heart Failure POC and LOC Devices Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott: Financials
Figure 57 F. Hoffmann-La Roche Ltd: Financials
Figure 58 Siemens Healthineers: Financials
Figure 59 QuidelOrtho Corporation: Financials
Figure 60 Jant Pharmacal Corporation: Financials
Figure 61 Trinity Biotech: Financials
Figure 62 bioM?rieux: Financials
Figure 63 Beckman Coulter, Inc.: Financials
